Abhijit Parolia
Overview
Explore the profile of Abhijit Parolia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tien J, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, et al.
Cell Rep Med
. 2024 Oct;
5(10):101758.
PMID: 39368479
Biallelic loss of cyclin-dependent kinase 12 (CDK12) defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. It remains unclear, however, whether CDK12 loss drives prostate cancer (PCa) development or uncovers pharmacologic...
2.
Parolia A, Eyunni S, Verma B, Young E, Liu Y, Liu L, et al.
Nat Genet
. 2024 Sep;
56(10):2132-2143.
PMID: 39251788
Androgen receptor (AR) is a ligand-responsive transcription factor that drives terminal differentiation of the prostatic luminal epithelia. By contrast, in tumors originating from these cells, AR chromatin occupancy is extensively...
3.
Canadas I, Casirati G, Houlahan K, Maxwell K, Mehta A, Parolia A, et al.
Cancer Discov
. 2024 Sep;
14(9):1584-1589.
PMID: 39228299
No abstract available.
4.
He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu X, et al.
Cancer Cell
. 2024 Jul;
42(8):1336-1351.e9.
PMID: 39029462
The POU2F3-POU2AF2/3 transcription factor complex is the master regulator of the tuft cell lineage and tuft cell-like small cell lung cancer (SCLC). Here, we identify a specific dependence of the...
5.
Yu J, Yan Y, Li S, Xu Y, Parolia A, Rizvi S, et al.
Cell
. 2024 Jul;
187(17):4713-4732.e19.
PMID: 38968937
Immune tolerance mechanisms are shared in cancer and pregnancy. Through cross-analyzing single-cell RNA-sequencing data from multiple human cancer types and the maternal-fetal interface, we found B7-H4 (VTCN1) is an onco-fetal...
6.
Choi J, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, et al.
Nat Commun
. 2024 Jun;
15(1):5487.
PMID: 38942798
Cancer treatment continues to shift from utilizing traditional therapies to targeted ones, such as protein kinase inhibitors and immunotherapy. Mobilizing dendritic cells (DC) and other myeloid cells with antigen presenting...
7.
Wang Y, Xue H, Zhu X, Lin D, Dong X, Chen Z, et al.
bioRxiv
. 2024 May;
PMID: 38746377
Background And Objective: Prostate cancer (PCa) is a leading cause of cancer mortality in men, with neuroendocrine prostate cancer (NEPC) representing a particularly resistant subtype. The role of transcription factors...
8.
Liu L, Parolia A, Liu Y, Hou C, He T, Qiao Y, et al.
J Med Chem
. 2024 Apr;
67(9):6938-6951.
PMID: 38687638
Nuclear receptor-binding SET domain-containing 2 (NSD2), a methyltransferase that primarily installs the dimethyl mark on lysine 36 of histone 3 (H3K36me2), has been recognized as a promising therapeutic target against...
9.
Miyahira A, Kamran S, Jamaspishvili T, Marshall C, Maxwell K, Parolia A, et al.
Prostate
. 2024 Apr;
84(11):993-1015.
PMID: 38682886
Introduction: The 2023 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, themed "Disrupting Prostate Cancer Research: Challenge Accepted," was convened at the University of California, Los Angeles, Luskin Conference Center, in Los...
10.
Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, et al.
Nature
. 2024 Apr;
629(8011):E9.
PMID: 38649489
No abstract available.